Europe Synthetic Biology Market

Europe Synthetic Biology Market Size (2023 to 2028)

The size of the Synthetic Biology Market in Europe was worth USD 1.71 billion in 2023 and is projected to grow at a CAGR of 23.21%, to reach USD 4.86 billion by 2028.

The rise in large-scale applications, such as the capacity to produce or create new and correct and carry out a gene, is driving the European synthetic biology market. Furthermore, heavy use of substances formed by a living organism to create a catalyst kit, gene synthesis products in academics or during the studies is further expected to accelerate the market's growth rate. Furthermore, the extensive usage of investigation of introduced and more desirable treatments, the quality of being able to private and public funding for the discovery of novel therapies are a big plus to the market’s growth rate.

Production or modification of living organisms, heredity material, biological systems, rise in research activities which form as a whole substance from two, of science, technology, and engineering to design, redesign or produce are estimated to create new growth possibilities for the market participants during the forecast period. In the European region, the rise in focus is because of the low price of the medicinal drugs prepared using machinery advantage provides opportunities for manufacturers.

Government policies, i.e., regulated or related to bio-war, biosafety, and biosecurity issues, are expected to act negatively on the market’s growth rate during the forecast period. Furthermore, competition or the increasing attempts to establish one’s superiority among the current market players may hamper the growth. Finally, ethical risk also hinders the development of the European synthetic biology market.

Advanced use of computers and design systems in synthetic biology has changed the traditional fight against genetic problems and new diseases. A few years back, to reach a specific rate or level, a bio-based economy is around making benefits in the market's regulatory environment. However, to translate research and development into profits and the ability to work successfully and rate the technology, there is a need to build the required infrastructure, which is expected to be challenging.

This research report on the European synthetic biology market has been segmented & sub-segmented into the following categories:

By Tool: 

• Chassis Organisms
• Cloning & Assembly Kits
• Oligonucleotide Synthesis
• Enzymes
• Xeno Nucleic Acid

By Technology: 

• Enabling technologies
  • Gene Synthesis
  • Cloning and Sequencing
  • Genome Engineering
  • Bioinformatics
  • Nanotechnology
  • Site-Directed Mutagenesis
  • Microfluidics
  • Measurement and Modelling
• Enabled technologies
  • Next-Generation Sequencing
  • Pathway Engineering

By Application: 

• Medical
• Environmental
• Industrial

By Country:

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark           
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

Regionally, the European synthetic biology market is predicted to occupy the second highest market share in the global market and is expected to continue holding that position during the forecast period. The market growth in the region is attributed to the increasingly large number of ongoing research activities and favorable reimbursement policies. In addition, significant boosts from European countries such as the UK, Germany, and France are helping the European market see new growth heights. 

The German synthetic biology market accounted for a significant share in the European market in 2022. The advancing healthcare sector, investment by leading companies, and establishment of small start-ups promote market growth. Also, the need for synthetic biology techniques is rising across the country since organisms produced with these techniques are very affordable due to their usage in different industrial applications, reducing research costs.

On the other hand, the countries such as UK, France, Spain, and Italy are anticipated to witness a considerable share and expand the European regional market growth. Due to the rising demand for synthetic biology in pharmaceutical and biotechnological companies for research and development and government funding and investments.

KEY MARKET PLAYERS:

Dupont, Intrexon Corporation, Amyris, Inc., Genscript USA, Inc., Integrated Dna Technologies (IDT), Inc., Novozymes, Royal DSM N.V, New England Biolabs, Inc., Synthetic Genomics, Inc., and Thermo Fisher Scientific, Inc. are some of the dominating companies in the Europe synthetic biologics market profiled in this report.